Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of GSBR-1290 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of GSBR-1290 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aleniglipron (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Avance Clinical Pty Ltd; Gasherbrum Bio

Most Recent Events

  • 26 Jun 2023 Results assessing safety, tolerability, and pharmacokinetics (PK) of a single dose of GSBR-1290 in Healthy Volunteers presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
  • 07 Jun 2023 According to a Structure Therapeutics media release, data from this study will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions taking place June 23-26, 2023, in San Diego, CA.
  • 01 Aug 2022 Results published in the Structure Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top